Protalix BioTherapeutics, Inc. (PLX) stock is tumbling today: Why is it so?
Shares of the Protalix BioTherapeutics, Inc. (PLX) stock were tumbling today following the release of the updated data related to the clinical development of PRX-102 for the treatment of patients suffering from Fabry Disease. PLX stock price saw a downtrend of 14.77% to drop at $2.54 a share as of this writing. At the previous […]
H.C. Wainwright reiterates Protalix BioTherapeutics Inc. [PLX] at Buy and assigns price target at $11
H.C. Wainwright maintained its Protalix BioTherapeutics Inc. [AMEX:PLX] rating to the equivalent of Buy but changed the price target to $11, in a research note dated December 31, 2020. That figure represents around a 212.5% premium from where the company’s shares closed on Wednesday. Other analysts also revised their coverage, with H.C. Wainwright’s analysts reiterating […]
